MedTrace Logo

Dendritic Cell Vaccination in Patients With Advanced Melanoma

NCT03092453 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2024-12-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate a method of using dendritic cells (a kind of white blood cell) as a vaccine to stimulate your own immune system to react to your melanoma cells.

Conditions

Interventions

BIOLOGICAL

Mature dendritic cell (DC) vaccine

Mature DC 7.5-15 million/peptide followed by 2 booster every six weeks of 1-5 million/peptide followed by standard of care anti PD-1 therapy.

DRUG

Cyclophosphamide 300mg/m^2

administered prior to subject's first DC dose

DRUG

Pembrolizumab

administered 7-8 weeks after subject's last DC dose

Sponsors & Collaborators

Principal Investigators

  • Gerald P Linette, MD, PhD · University of Pennsylvania

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-01
Primary Completion
2023-03-31
Completion
2023-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03092453 on ClinicalTrials.gov